OKUR Valuation

Onkure Therapeutics Inc

Add to Watchlist

Advanced Chart

2.300

+0.02(0.877%)1D

Overview
Forecast
Valuation
Earnings

OKUR Relative Valuation

OKUR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, OKUR is overvalued; if below, it's undervalued.

Historical Valuation

Onkure Therapeutics Inc (OKUR) is now in the Fair zone, suggesting that its current forward PS ratio of 256.16 is considered Fairly compared with the five-year average of -1.99. The fair price of Onkure Therapeutics Inc (OKUR) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：2.34

Fair

-0.53

Trailing

Forward

0.00

EV/EBITDA

Onkure Therapeutics Inc. (OKUR) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

0.88

EV/EBIT

Onkure Therapeutics Inc. (OKUR) has a current EV/EBIT of 0.88. The 5-year average EV/EBIT is -2.05. The thresholds are as follows: Strongly Undervalued below -7.70, Undervalued between -7.70 and -4.88, Fairly Valued between 0.78 and -4.88, Overvalued between 0.78 and 3.60, and Strongly Overvalued above 3.60. The current Forward EV/EBIT of 0.88 falls within the Overvalued range.

249.67

Onkure Therapeutics Inc. (OKUR) has a current PS of 249.67. The 5-year average PS is 101.97. The thresholds are as follows: Strongly Undervalued below -125.11, Undervalued between -125.11 and -11.57, Fairly Valued between 215.51 and -11.57, Overvalued between 215.51 and 329.05, and Strongly Overvalued above 329.05. The current Forward PS of 249.67 falls within the Overvalued range.

-0.60

P/OCF

Onkure Therapeutics Inc. (OKUR) has a current P/OCF of -0.60. The 5-year average P/OCF is -0.59. The thresholds are as follows: Strongly Undervalued below -1.64, Undervalued between -1.64 and -1.12, Fairly Valued between -0.07 and -1.12, Overvalued between -0.07 and 0.46, and Strongly Overvalued above 0.46. The current Forward P/OCF of -0.60 falls within the Historic Trend Line -Fairly Valued range.

-0.60

P/FCF

Onkure Therapeutics Inc. (OKUR) has a current P/FCF of -0.60. The 5-year average P/FCF is -0.59. The thresholds are as follows: Strongly Undervalued below -1.64, Undervalued between -1.64 and -1.11, Fairly Valued between -0.07 and -1.11, Overvalued between -0.07 and 0.46, and Strongly Overvalued above 0.46. The current Forward P/FCF of -0.60 falls within the Historic Trend Line -Fairly Valued range.

Onkure Therapeutics Inc (OKUR) has a current Price-to-Book (P/B) ratio of 0.34. Compared to its 3-year average P/B ratio of -0.23 , the current P/B ratio is approximately -252.24% higher. Relative to its 5-year average P/B ratio of -0.23, the current P/B ratio is about -252.24% higher. Onkure Therapeutics Inc (OKUR) has a Forward Free Cash Flow (FCF) yield of approximately -170.38%. Compared to its 3-year average FCF yield of -89.91%, the current FCF yield is approximately 89.50% lower. Relative to its 5-year average FCF yield of -89.91% , the current FCF yield is about 89.50% lower.

0.34

P/B

Median3y

-0.23

Median5y

-0.23

-174.80

FCF Yield

Median3y

-89.91

Median5y

-89.91

Competitors Valuation Multiple

The average P/S ratio for OKUR's competitors is 43.78, providing a benchmark for relative valuation. Onkure Therapeutics Inc Corp (OKUR) exhibits a P/S ratio of 249.67, which is 470.35% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

OKUR.O

Onkure Therapeutics Inc

Tempest Therapeutics Inc

Loss

31.71M

SLGL.O

Sol Gel Technologies Ltd

Plus Therapeutics Inc

Reviva Pharmaceuticals Holdings Inc

Loss

23.52M

Performance Decomposition

Market capitalization of OKUR increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of OKUR in the past 1 year is driven by Unknown.